Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is gearing up for the sixth annual BOTOX® Cosmetic Day, set for Wednesday, November 20, 2024. This special day celebrates the healthcare providers…
AstraZeneca will present new data from its cutting-edge hematology portfolio and pipeline at the 66th American Society of Hematology (ASH) Annual Meeting, taking place from December 7 to 10, 2024.…
WuXi Biologics (“WuXi Bio”) (2269.HK), a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings…
Second Round of Polio Vaccination Campaign in Gaza Completed Amid Ongoing Conflict: UNICEF and WHO The second round of the polio vaccination campaign in the Gaza Strip concluded yesterday, with…
The Access and Allocation Mechanism (AAM) for mpox has allocated an initial 899,000 vaccine doses to nine African countries severely impacted by the ongoing mpox outbreak. This distribution, made in…
The recently released Global Tuberculosis Report 2024 provides an updated overview of the challenges and progress in the global fight against tuberculosis (TB) during 2023. TB affected 10.8 million people…
Sarepta Therapeutics a leader in precision genetic medicine for rare diseases, has announced its financial results for the third quarter of 2024, showcasing strong revenue growth and significant progress in…
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, will showcase new findings from the Phase 3 CARTITUDE-4 trial on minimal residual disease (MRD) negativity rates in multiple…
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported its financial results for the third quarter ending September 30, 2024. Teva’s President and CEO, Richard Francis, commented, “We’ve achieved…
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced the design of a pivotal Phase 3 clinical trial for ION582, an investigational treatment for Angelman syndrome (AS), following successful alignment with the…
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-driven cancers, reported its third-quarter financial results for the period ending September 30, 2024, and…
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company developing transformative gene-based medicines for serious diseases, has released its financial results for Q3 ending September 30, 2024. “We are making strong progress…